ストックスクリーナーアプリを入手
9.585
4.98%
0.455
アフターアワーズ：
9.64
0.055
+0.57%
前日終値:
$9.13
開ける：
$9.24
24時間の取引高:
665.21K
Relative Volume:
0.79
時価総額：
$511.61M
収益：
$27.46M
当期純損益:
$-46.05M
株価収益率:
-10.20
EPS:
-0.94
ネットキャッシュフロー:
$-33.83M
1週間 パフォーマンス:
+11.19%
1か月 パフォーマンス:
+14.93%
6か月 パフォーマンス:
+107.02%
1年 パフォーマンス:
+115.88%
1日の値動き範囲:
$9.15
$9.64
1週間の範囲:
$8.325
$9.64
52週間の値動き範囲:
$4.20
$9.64
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
名前
Zevra Therapeutics Inc
セクター
電話
(321) 939-3416
住所
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
ZVRA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| ZVRA | 9.585 | 511.61M | 27.46M | -46.05M | -33.83M | -0.94 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-03-17 | 開始されました | Maxim Group | Buy |
Zevra Therapeutics Inc (ZVRA) 最新ニュース
Zevra Therapeutics (NASDAQ:ZVRA) Reaches New 52-Week HighShould You Buy? - MarketBeat
Zevra Therapeutics Launches MIPLYFFA for Niemann-Pick Disease - Yahoo Finance
ZVRA stock touches 52-week high at $9.6 amid robust growth - Investing.com UK
Research Analysts Offer Predictions for ZVRA FY2024 Earnings - MarketBeat
Zevra launches first FDA-approved NPC treatment By Investing.com - Investing.com Australia
Zevra launches first FDA-approved NPC treatment - Investing.com India
Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C - Yahoo Finance
HC Wainwright Expects Lower Earnings for Zevra Therapeutics - MarketBeat
Zevra Therapeutics (NASDAQ:ZVRA) Earns "Buy" Rating from HC Wainwright - MarketBeat
Guggenheim Initiates Coverage of Zevra Therapeutics (ZVRA) with Buy Recommendation - MSN
Zevra Therapeutics (STU:1GDA) Enterprise Value : €424.12 Mil (As of Nov. 20, 2024) - GuruFocus.com
Zevra Therapeutics Q3 2024 Earnings Preview - MSN
Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates - MSN
(ZVRA) Technical Pivots with Risk Controls - Stock Traders Daily
ZVRA FY2024 EPS Forecast Decreased by Cantor Fitzgerald - MarketBeat
What is William Blair's Forecast for ZVRA FY2024 Earnings? - MarketBeat
Analysts Have Made A Financial Statement On Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Third-Quarter Report - Yahoo Finance
Zevra testing beta blocker celiprolol for vEDS in Phase 3 US study - Ehlers-Danlos News
Simplify Asset Management Inc. Invests $833,000 in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
What is William Blair's Estimate for ZVRA FY2026 Earnings? - MarketBeat
Here's What Analysts Are Forecasting For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Third-Quarter Results - Simply Wall St
Roth Capital Forecasts Lower Earnings for Zevra Therapeutics - MarketBeat
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Sees Large Decline in Short Interest - MarketBeat
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Zevra Therapeutics reports Q3 financial results - Investing.com
Canaccord Genuity Group Issues Pessimistic Forecast for Zevra Therapeutics (NASDAQ:ZVRA) Stock Price - MarketBeat
Q4 Earnings Forecast for ZVRA Issued By Roth Capital - MarketBeat
Zevra Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Woodline Partners LP's Strategic Acquisition of Zevra Therapeuti - GuruFocus.com
Zevra Therapeutics' SWOT analysis: rare disease drug maker's stock poised for growth - Investing.com
Janney Montgomery Scott LLC Sells 127,755 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Financial Challenges - GuruFocus.com
Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... - Yahoo Finance
Zevra Therapeutics’ Transformative Third Quarter 2024 - TipRanks
Zevra Therapeutics: Q3 Earnings Snapshot - San Francisco Chronicle
Zevra Therapeutics earnings missed by $0.28, revenue fell short of estimates - Investing.com UK
Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates - The Manila Times
Zevra Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... By GuruFocus - Investing.com Canada
Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting - The Manila Times
Zevra Therapeutics Inc (ZVRA) Q3 2024: Everything You Need To Kn - GuruFocus.com
Zevra Therapeutics Validates Key Clinical Scale for Niemann-Pick Disease Treatment Study | ZVRA Stock News - StockTitan
International Assets Investment Management LLC Raises Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
(ZVRA) Pivots Trading Plans and Risk Controls - Stock Traders Daily
ZVRA stock touches 52-week high at $8.96 amid market rally - Investing.com India
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $20.83 Average PT from Analysts - MarketBeat
Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13 - The Manila Times
Zevra Therapeutics CEO to Present at Guggenheim Healthcare Conference | ZVRA Stock News - StockTitan
Zevra Therapeutics (ZVRA) to Release Quarterly Earnings on Tuesday - MarketBeat
Vanguard Group Inc's Strategic Acquisition in Zevra Therapeutics Inc - GuruFocus.com
Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024 - The Manila Times
Zevra Therapeutics Inc (ZVRA) 財務データ
収益
当期純利益
現金流量
EPS
Zevra Therapeutics Inc (ZVRA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Clifton R. LaDuane | CFO & Treasurer |
Jul 17 '24 |
Buy |
6.77 |
2,000 |
13,540 |
18,469 |
| Anderson Thomas | Director |
Jul 16 '24 |
Buy |
6.81 |
10,000 |
68,065 |
20,000 |
| Bode John B | Director |
Jul 12 '24 |
Buy |
5.87 |
10,000 |
58,661 |
30,000 |
1.89%
2.08%
大文字化:
|
ボリューム (24 時間):